Join our daily newsletter At The Bell to receive exclusive market insights
- Immutep (IMM) enters a trading halt while it plans the details of an upcoming capital raising
- The biotech company will remain in the halt until June 21 or when more details regarding the raise are released, whichever occurs first
- On June 8, Immutep revealed it is starting a research program as part of its clinical development pipeline
- The company will continue working with Cardiff University to develop a small molecule anti-LAG treatment for cancer patients
- Shares in Immutep last traded at 61.5 cents on June 16
Immutep (IMM) has entered a trading halt while it plans the details of an upcoming capital raising.
The biotech company will remain in the halt until June 21 or when more details regarding the raise are released, whichever occurs first.
Immutep is yet to disclose how much it intends to raise or what it will use the funds for once received.
On June 8, Immutep revealed it is starting a research program as part of its clinical development pipeline of immunotherapies for cancer and autoimmune disease.
The company will continue working with Cardiff University to develop a small molecule anti-LAG treatment for cancer patients.
The aim of this research program is to make a treatment that can be delivered orally and at a lower cost than other options.
Intellectual property arising from the program will be jointly owned by both Immutep and Cardiff University with IMM to retain the exclusive rights to develop and commercialise any new products.
Shares in Immutep last traded at 61.5 cents on June 16. The company has a $443.8 million market cap.
